LPLeila A. Pak

Leila A. Pak

*This is an algorithmically generated author record based on publicly available information.

Leila A. Pak has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perinatal risk factors for asphyxia and the occurrence of hypoxic-ischemic encephalopathy in newborns

    by N. I. Zakharova, L. A. Pak, L. V. Malyutina, A. S. Petrova, E. V. Brezhneva, S. N. Lavrentiev, M. V. Kondratyev, A. S. Gryzunova, M. A. Shvedova, M. A. Pozdnyakova, et al.

    Intranatal asphyxia and hypoxic-ischemic encephalopathy of newborns are caused by risk factors from both the mother and the fetus, which makes the pathophysiology of this condition extremely difficult. Data from the federal statistical observation form No. 32 for the Moscow region show minor changes in the number of chronic diseases, a burdened obstetric and gynecological history, as well as pathology during pregnancy and childbirth in pregnant women over 3 years Perinatal risk factors were significantly more common in newborns with severe intranatal asphyxia and HIE compared with a moderate degree who underwent a therapeutic hypothremia procedure. Complications during the birth process, surgical methods of rapid fetal extraction (vacuum extractor) were the causal factors of asphyxia. To a minor extent, the asphyxia of the newborn is affected by the untimely discharge of amniotic fluid.

  • RARE CASE OF HYPERSENSITIVITY REACTION TO ENZYME REPLACEMENT THERAPY IN A CHILD WITH TYPE 3 GAUCHER DISEASE

    by G.B. Movsisyan, A.A. Roppelt, D.V. Yukhacheva, A.Yu. Shcherbina, N.C. Smetanina, K.V. Savostyanov, L.A. Pak, A.A. Pushkov, N.N. Mazanova, R.V. Ponomarev, et al.

    Gaucher disease (GD) is an autosomal recessive disease that leads to excessive accumulation of glucocerebroside in the cells of the reticuloendothelial system, which leads to multiple organ damage with the development of cytopenia, hepatosplenomegaly, bone and neurological pathology. An effective and safe enzyme replacement therapy has been developed for the treatment of GD. However, there are rare cases of hypersensitivity reactions presented in the literature, requiring individualization of patient management with the search for alternative ways to continue therapy and prevent side effects. We present a rare clinical case of intolerance to imiglucerase and velaglucerase alfa in a child with GD type 3 and possible methods for continuing treatment, taking into account the hypersensitivity reaction.

  • Combined impact of myofascial techniques and gymnastics for the rehabilitation of children with neuropathy of the facial nerve

    by Галина Сергеевна Лупандина-Болотова, Sergey D. Polyakov, Lale A. Pak, Aliya A. Revina, Olga V. Ashtaeva

    Facial neuropathy (Bell’s palsy) is a disease characterized by damage to the nerve fibers of the VII cranial nerve with the occurrence of unilateral facial muscle weakness or paralysis. Damage to the facial nerve is the most common type of cranial neuropathy. Delayed treatment onset and/or inadequate therapy of the disease leads to the residual neurological deficit, which may significantly reduce the patient’s quality of life. The best result in the rehabilitation of children with facial nerve neuropathy is provided with an integrated approach using myofascial manual therapy techniques and exercises. This is achieved during the therapy sessions with a myofascial manual techniques complex. After preparing the muscles, fascia and skin, the therapist conducts a set of passive and active exercises with a patient to restore the work of his/her facial muscles. The method was created, tested, and implemented in the Federal State Autonomous Institution “National Medical Research Center of Children’s Health” of the Ministry of Health of the Russian Federation. The essence of the method consists of the process of therapy sessions, providing a gradual recovery of functional relationships between the myofascial structures of the face, and improvement of lymphatic drainage, arterial blood supply, and venous outflow restoration. The alternation of myofascial manual techniques with exercises contributes to the maximum effective restoration of the symmetrical work of the facial muscles. Evaluation of the effectiveness of myofascial manual techniques and corrective exercises was carried out by clinical presentation changes and follow-up data. Comprehensive rehabilitation using myofascial manual techniques and exercises makes it possible to achieve improvement in restoring the function of facial muscles, eliminating asymmetry, and preventing complications. Conclusion. The obtained results demonstrated the effectiveness of myofascial manual techniques and exercises in the rehabilitation of children with facial neuropathy. Based on the results of the study, a positive effect of this method was shown to improve the functions of mimic muscles and facial symmetry in children with Bell’s palsy.

  • Molecular genetic diagnosis of speech disorders in children

    by Лолита Алиевна Пак, Kirill V. Savostyanov, Lyudmila M. Kuzenkova, Alexander A. Pushkov, Ilya S. Zhanin, Eugeniya V. Uvakina

    Introduction. Speech disorders (SD) are one of the urgent problems of childhood neurology. Despite the long history of studying speech disorders in children, the use of modern instrumental research in the diagnosis, the use of various therapeutic techniques for their correction, scientific interest in understanding the pathogenetic foundations of these disorders remains relatively high. In recent years, much attention has been paid to studying the genetic causes of the development of this pathology. Currently, data are presented on more than 20 candidate genes that may determine isolated speech disorders or their combination with other cognitive disorders. The study of the molecular and genetic foundations of speech disorders in children will expand clinicians’ understanding of the pathogenesis of speech disorders and optimize diagnostic approaches. The aim of the study is to investigate the structure of SD and diseases and to define clinically significant nucleotide variants leading to various diseases, the phenotype of which includes SD. Materials and methods. One hundred sixty 2 to 7-year children with speech disorders aged were under observation, 93 (58.1%) girls and 67 (41.9%) boys were hospitalized into the Department of Neuropsychiatry and psychosomatic pathology and the Department of Pathology of early Childhood of the of National Medical Research Center for Children’s Health of the Ministry of Health of Russian Federation. All observed patients underwent sequencing of the clinical exome by mass parallel sequencing. Results. Sequencing the clinical exome in SD children makes it possible to detect clinically significant nucleotide variants leading to various diseases, including speech disorders. The most common speech disorders in children are clinical manifestations of hereditary diseases. In 5 (3.1%) of the observed patients, nucleotide variants were found during a molecular genetic study that can cause diseases in which speech and intellectual-mnestic disorders are among the main clinical manifestations. Conclusion. There were studied molecular genetic features of speech disorders in 160 children. The continuation of clinical studies aimed at searching for pathogenic genome variants leading to speech and intellectual-mnestic disorders in a representative sample of patients with speech disorders will resolve the issue of the feasibility of including sequencing of the clinical exome in the diagnostic algorithm of speech disorders in children.


  • A clinical case of severe Duchenne muscular dystrophy caused by a nonsense mutation in the DMD gene in a girl

    by Татьяна Владимировна Подклетнова, Olga B. Kondakova, Eugeniya V. Uvakina, Dariya A. Fisenko, Anastasiya A. Lyalina, Sophiya G. Popovich, Lyudmila M. Kuzenkova, Aleksey L. Kurenkov, Lale A. Pak, Bella I. Bursagova, et al.

    Duchenne muscular dystrophy (DMD) is a hereditary progressive muscular dystrophy, mainly manifested in boys, is characterized by the onset at an early age, gradual symmetrical atrophy of the striated musculature of the limbs, trunk, as well as damage to the heart muscle. As a rule, girls and women inheriting a pathological mutation are classified only as its carriers and do not have clinical manifestations of the disease. Rare cases when women or girls show clinical manifestations of DMD may be due to chromosomal rearrangements involving the region of the short arm of the X chromosome (Xp21.2), deletions of this region, complete loss of the X chromosome (Shereshevsky-Turner syndrome), homogenous X chromosome dysomnia, compound heterozygous state for two pathogenic mutations in the DMD gene, nonequilibrium inactivation of the X chromosome. When female mutation carriers have DMD clinical symptoms, they usually manifest much milder than boys and young males. Descriptions of patients with the severe course and rapid progression of the disease, comparable in the rate of progression with boys, are rare. In this article, the authors share their experience of observing a girl patient who suffered from a severe form of DMD.


  • Somatoneurological and psycho-pedagogical features of children with cerebral palsy in the context of their readiness for training in Paralympic sports

    by Лолита Алиевна Пак, Svetlana B. Lazurenko, Svetlana B. Makarova, Tatyana V. Sviridova, Lyudmila M. Kuzenkova, Alexey L. Kurenkov, Bella I. Bursagova, Tamara R. Chumbadze

    Introduction. Currently, Russia does not have a scientifically grounded medical and psychological support system for disabled children (DC), which allows involving them in classes in children and youth schools of adaptive physical education, preparing the country’s Paralympic DC reserve. Aim of the study. To develop and create a medical support system for the Paralympic DC reserve, capable of improving their quality of life and forming a medical and social lift. Materials and methods. Children aged from 1 year to 18 years had cerebral palsy (CP) with impaired motor functions of levels I and II according to the global motor function assessment system and the Manual Abilities Classification system and their families were monitored. A comprehensive assessment of the somatic, neurological, mental and nutritional status of CP children) was carried out, and a wide range of comorbid pathology was described. After the rehabilitation treatment with the use of complex personalized rehabilitation programs, dynamic monitoring of the condition of patients with cerebral palsy was carried out, followed by an assessment of the effectiveness of rehabilitation treatment and the impact on it the psychological readiness of patients, their parents to engage in Paralympic sports, as well as the socio-economic level of the family. The attitude of CP children and their parents to participate in the Paralympic movement was studied. All patients underwent a comprehensive study of somatic, neurological, orthopaedic, psychological and nutritional status. The socio-hygienic characteristics of families and the rehabilitation potential of DC and their families have been determined. Results. Children with cerebral palsy have a wide range of comorbid pathology, which requires the involvement of specialists of different profiles in the curation of patients. The use of complex personalized rehabilitation programs allows achieving positive dynamics after 14 days of rehabilitation treatment. Early introduction of botulinum therapy in the rehabilitation program of CP patients provides higher efficiency of rehabilitation treatment. Treatment of protein-energy deficiency in CP children should include correction of the diet using specialized products, metabolic therapy, enzyme and complex vitamin preparations. Differentiated medical, psychological and pedagogical counselling of parents of CP children will allow optimizing the solution of the state problem regarding the timely inclusion of persons with disabilities in adaptive physical education classes. Conclusion. The development and creation of a comprehensive medical and psychological support system solve an urgent medical and social problem, ensuring the integration of DC into society and improving the quality of life of both a sick child and his family members.

  • Differential diagnosis of Duchenne muscular dystrophy

    by Алексей Львович Куренков, Lyudmila M. Kuzenkova, Lale A. Pak, Bella I. Bursagova, Tatyana V. Podkletnova, Olga B. Kondakova, Anastasiya A. Lyalina, Dmitry I. Grebenkin, Aleksey A. Pushkov, Iulia I. Davydova, et al.

    Duchenne muscular dystrophy (DMD) is a disease with an X-linked recessive type of inheritance, belonging to a group of disorders with primary muscle damage, caused by pathogenic variants in the DMD gene and associated with dysfunction of the dystrophin protein. Since DMD is manifested by the gradual development of progressive, mainly proximal muscle weakness, the differential diagnosis is primarily carried out in the group of diseases with muscle damage - myopathies. Among these diseases, the leading candidates for differential diagnosis are hereditary myopathies (limb-girdle muscular dystrophies, facioscapulohumeral dystrophy, congenital muscular dystrophies, glycogenoses - the most common juvenile form of glycogenosis type II (Pompe disease)) and, much less often, congenital myopathies and other conditions of neuromuscular diseases). When conducting a differential diagnosis in a child with suspected DMD, the age of the onset of the disease, early initial clinical manifestations and the development of symptoms as they grow, genealogical analysis, laboratory tests (the level of creatine kinase, aspartate aminotransferase, alanine aminotransferase in blood serum), instrumental (electromyography, magnetic resonance imaging of the brain and muscles) and molecular genetics (polymerase chain reaction, multiplex ligation-dependent probe amplification, next-generation sequencing, Sanger sequencing, etc.) of studies, and in some cases, muscle biopsy data. Knowledge of the nuances of the differential diagnosis allows establishing a genetic diagnosis of DMD as early as possible, which is extremely important for the formation of the prognosis of the disease and the implementation of all available treatment methods, including pathogenetic therapy, and is also necessary for medical and genetic counselling of families with DMD patients.


  • Open Access

    Infantile parkinsonism-dystonia, type 1 (case report)

    by Lyudmila M. Kuzenkova, Lale A. Pak, Olga B. Kondakova, Anastasia A. Lyalina, Polina G. Tsygankova, Ilya V. Kanivets, Dmitry I. Grebenkin, Natalia V. Lapshina

    Infantile parkinsonism-dystonia, type 1 (DTDS) (OMIM 613135) is a rare inherited autosomal recessive disease that manifests in infancy. The development of the disease is caused by a homozygous or compound-heterozygous mutation in theSLC6A3gene (OMIM 126455), which encodes a dopamine Transporter localized on the short arm of chromosome 5 (5p15). The main pathogenetic mechanism of the disease is the loss of the function of the main dopamine transporter at the presynaptic level, which leads to a decrease in the reuptake of dopamine in the synaptic cleft, depletion of presynaptic dopamine reserves, and an increase in the amount of extraneuronal dopamine. Currently, there are 20 cases of this disease in children in the world. The main clinical manifestations of DTDS are various hyperkinesis patterns (dystonia, chorea, athetosis, etc.), followed by hypokinesia and rigidity, developing against the background of axial hypotension. Difficulties in differential diagnosis lead to the fact that many patients are observed for years with erroneous clinical diagnoses, including cerebral palsy, regularly receiving rehabilitation treatment without clinical effect. The mentioned above explains the need for clinicians to be aware of a rare disease DTDS, which will avoid diagnostic errors, prescribe adequate therapy promptly, and thereby significantly improve the quality of life of patients and their families. The article contains an overview of the etiological, pathogenetic, epidemiological, diagnostic, and therapeutic aspects of DTDS. For the first time in Russia, there is reported a clinical case of this rare disease, which presents the own experience with DTDS patient.


  • Open Access

    Clinical experience of replacing enzyme replacement therapy in a patient with mucopolysaccharidosis type II

    by Lyudmila M. Kuzenkova, Tatyana V. Podkletnova, Lale A. Pak, Oksana A. Ereshko

    Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an inherited chronic progressive lysosomal disease associated with recessive X-linked inheritance. MPS II is classified as an orphan disease and occurs at a rate of 1.3 per 100,000 white boys. Hunter syndrome is the most common type of mucopolysaccharidosis, accounting for about 50% of MPS types. The diseases pathogenesis is based on a violation of the stepwise cleavage of glycosaminoglycans (GAG) heparansulfate and dermatansulfate caused by a deficiency of the iduronate-2-sulfatase enzyme encoded by theIDSgene. The existing deficiency or complete absence of iduronate-2-sulfatase leads to a violation of the final stage of glycosaminoglycan catabolism and the accumulation heparansulfate and dermatansulfate in all organs and tissues. Currently, there are two drugs registered in the Russian Federation for pathogenetic enzyme replacement therapy of MPS: idursulfase and idursulfase beta. This refers to the expansion of the therapeutic options for Hunter syndrome patients in the event of severe adverse events. It allows choosing the treatment regimen that will be optimal for the patient and will significantly improve the quality of life. In this article, the authors share their own experience of changing enzyme replacement therapy in an MPS II child patient.


  • Open Access

    CEREBRAL PALSY: DIAGNOSTIC ERRORS

    by Lale A. Pak, L. M. Kuzenkova, A. L. Kurenkov, B. I. Bursagova

    The authors present the own clinical observation of a child with mucopolysaccharidosis type III, received the long-term rehabilitation treatment according to the false diagnosis of cerebral palsy.